Until June 2014, Chris BUYSE was CFO at ThromboGenics NV. He has 25 years of experience in international company finance and in running and establishing best financial practice. He was previously CFO of the Belgian biotechnology company CropDesign, where he coordinated its acquisition by BASF in early 2007. Before this, Mr. Buyse was Finance Director of WorldCom/MCI Belux, and was CFO and interim CEO of Keyware Technologies, In addition, he held several financial positions at Suez Lyonnaise des Eaux and Unilever.
He is currently serving as an independent board member of a few companies, mostly active in life sciences such as Celyad, Bone Therapeutics, Iteos and Bioxodes. He is managing partner of Fund+, an investment company founded on the initiative of emeritus Désiré Collen.